Seres Therapeutics (NASDAQ:MCRB) Raised to “Hold” at StockNews.com
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Thursday. Several other equities research analysts have also recently issued reports on MCRB. Chardan Capital reaffirmed a “buy” rating and set a $1.25 price target on shares of Seres […]
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Thursday. Several other equities research analysts have also recently issued reports on MCRB. Chardan Capital reaffirmed a “buy” rating and set a $1.25 price target on shares of Seres […]
